- Home
- BCTX vs AMZE Comparison
BCTX vs AMZE Comparison
Compare BCTX & AMZE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCTX
- AMZE
- Stock Information
- Founded
- BCTX 2014
- AMZE 2019
- Country
- BCTX Canada
- AMZE United States
- Employees
- BCTX N/A
- AMZE N/A
- Industry
- BCTX Biotechnology: Pharmaceutical Preparations
- AMZE Beverages (Production/Distribution)
- Sector
- BCTX Health Care
- AMZE Consumer Staples
- Exchange
- BCTX Nasdaq
- AMZE Nasdaq
- Market Cap
- BCTX 14.4M
- AMZE 16.1M
- IPO Year
- BCTX N/A
- AMZE 2021
- Fundamental
- Price
- BCTX $7.72
- AMZE $2.12
- Analyst Decision
- BCTX Strong Buy
- AMZE
- Analyst Count
- BCTX 1
- AMZE 0
- Target Price
- BCTX $40.00
- AMZE N/A
- AVG Volume (30 Days)
- BCTX 92.9K
- AMZE 75.3K
- Earning Date
- BCTX 10-28-2025
- AMZE 08-14-2025
- Dividend Yield
- BCTX N/A
- AMZE N/A
- EPS Growth
- BCTX N/A
- AMZE N/A
- EPS
- BCTX N/A
- AMZE N/A
- Revenue
- BCTX N/A
- AMZE $1,054,111.00
- Revenue This Year
- BCTX N/A
- AMZE $6,741.66
- Revenue Next Year
- BCTX N/A
- AMZE $100.61
- P/E Ratio
- BCTX N/A
- AMZE N/A
- Revenue Growth
- BCTX N/A
- AMZE N/A
- 52 Week Low
- BCTX $6.00
- AMZE $2.00
- 52 Week High
- BCTX $294.00
- AMZE $28.72
- Technical
- Relative Strength Index (RSI)
- BCTX 40.75
- AMZE 29.59
- Support Level
- BCTX $7.28
- AMZE $2.35
- Resistance Level
- BCTX $8.82
- AMZE $3.28
- Average True Range (ATR)
- BCTX 0.74
- AMZE 0.28
- MACD
- BCTX 0.58
- AMZE 0.07
- Stochastic Oscillator
- BCTX 60.82
- AMZE 9.49
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
About AMZE Amaze Holdings Inc. Common Stock
Amaze Holdings Inc is engaged in producer of low carb, low calorie, premium wines in the United States. The company offers bold, crisp, and creamy wines that embody health, warmth, and a deeper connection to wellness and an active lifestyle. The company currently sell seven proprietary varietals: Cabernet Sauvignon, Pinot Noir, Chardonnay, Sauvignon Blanc, Rose, Sparkling Rose, and a limited Reserve Napa Cabernet Sauvignon.